Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma

Summary EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, D...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2024-08, Vol.30 (16), p.3358-3360
Main Authors: Ohmura, Shunya, Grünewald, Thomas G. P.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy. See related article by Jess et al., p. 3533
ISSN:1078-0432
1557-3265
1557-3265
DOI:10.1158/1078-0432.CCR-24-1047